GlassScriptPhysician profile
Benjamin Ross Niland
NPI 1346689163
$4,287.48
in general payments reported to CMS, 2019-2025
30 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $121 · 2021: $107 · 2022: $504 · 2023: $894 · 2024: $1,388 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,251 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.32 |
| Education | $112.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,446.25 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $291.66 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $273.87 | 2020-2025 | Tremfya, Stelara |
| Enterra Medical, INC. | $229.87 | 2024 | |
| Pfizer INC. | $226.74 | 2020-2025 | |
| Genzyme Corporation | $211.02 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.33 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $171.41 | 2024 | Iqirvo, Bylvay |
| Erbe USA INC | $125.00 | 2022-2025 | Vio3 |
| Endogastric Solutions, INC | $124.10 | 2023 | Esophyx |
| Ferring Pharmaceuticals INC. | $120.41 | 2023-2025 | Rebyota, Cimzia |
| Celgene Corporation | $98.41 | 2023-2024 | Zeposia |
| Covidien LP | $91.20 | 2019 | |
| Lilly USA, LLC | $87.44 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $73.83 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mahana Therapeutics, INC. | $72.97 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $64.86 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $55.98 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $50.83 | 2023-2025 | Ibsrela |
| Exact Sciences Corporation | $48.43 | 2023-2024 | Cologuard Collection Kit |
| Olympus America INC. | $39.69 | 2023-2024 | Evis Exera Lll Colonovideoscope, Evis Exera III Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Ironwood Pharmaceuticals, INC | $38.32 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $37.09 | 2022-2023 | Ocaliva |
| Daiichi Sankyo INC. | $32.71 | 2022 | |
| Qol Medical, LLC | $18.47 | 2024 | Sucraid |
| Redhill Biopharma INC. | $17.06 | 2021 | |
| Aimmune Therapeutics, INC. | $13.81 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.16 | 2024 | Cyltezo |
| Janssen Pharmaceuticals, INC | $11.79 | 2021 | |
| Laborie Medical Technologies Corp. | $9.77 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Niland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.